NO872581L - Et produksjon av antistoffer ved anvendelse av insolubil iserte immunkomplekser. - Google Patents

Et produksjon av antistoffer ved anvendelse av insolubil iserte immunkomplekser.

Info

Publication number
NO872581L
NO872581L NO872581A NO872581A NO872581L NO 872581 L NO872581 L NO 872581L NO 872581 A NO872581 A NO 872581A NO 872581 A NO872581 A NO 872581A NO 872581 L NO872581 L NO 872581L
Authority
NO
Norway
Prior art keywords
insolubilized
antibodies
antigen
immune complexes
antibody
Prior art date
Application number
NO872581A
Other languages
English (en)
Other versions
NO872581D0 (no
Inventor
Alton C Morgan Jr
Clive S Woodhouse
Robert F Mcintyre
Original Assignee
Neorx Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neorx Corp filed Critical Neorx Corp
Publication of NO872581D0 publication Critical patent/NO872581D0/no
Publication of NO872581L publication Critical patent/NO872581L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/622—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier non-covalent binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

En fremgangsmåte for forbedring av produksjon av antistoffer gjennom immunosering med insolubiliserte immunkomplekser er beskrevet. Renset antigen eller heterogene antigenblandinger kan kombineres med polyklonalt eller monoklonalt antistoff og det resulterende kompleks blir bundet til insolubilisert protein A for å danne insolubiliserte immunkomplekser. Fremgangsmåter for forbedring av immunogeniteten av et leselig antigen og for produksjon av monoklonale anti-idiotypiske antistoffer er også beskrevet. Monoklonale antistoffer som er spesifikke for en spesiell, ennå ugjenkjent epitop, kan produseres ved en annen beskrevet fremgangsmåte. Insolubiliserte immunkomplekser, som omfatter er.tigen cg antistoff som enten er direkte bandet tii sefarose -ll = r absorbert på insolubilisert protein A og iir.munosorbenter, so- omfatter antistoff absorbert på insolubilisert protein A, også beskrevet.
NO872581A 1986-06-20 1987-06-19 Et produksjon av antistoffer ved anvendelse av insolubil iserte immunkomplekser. NO872581L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87682886A 1986-06-20 1986-06-20
US07/024,632 US4879225A (en) 1986-06-20 1987-03-11 Enhanced production of antibodies utilizing insolubilized immune complexes

Publications (2)

Publication Number Publication Date
NO872581D0 NO872581D0 (no) 1987-06-19
NO872581L true NO872581L (no) 1987-12-21

Family

ID=26698676

Family Applications (1)

Application Number Title Priority Date Filing Date
NO872581A NO872581L (no) 1986-06-20 1987-06-19 Et produksjon av antistoffer ved anvendelse av insolubil iserte immunkomplekser.

Country Status (7)

Country Link
US (1) US4879225A (no)
EP (1) EP0251065A3 (no)
JP (1) JPS63258496A (no)
CN (1) CN87105716A (no)
AU (1) AU615628B2 (no)
DK (1) DK315187A (no)
NO (1) NO872581L (no)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3565289A (en) * 1988-05-05 1989-11-29 National Research Development Corporation Immunogenic complex and its use in vaccination
EP0529007A1 (en) 1990-04-18 1993-03-03 The Regents Of The University Of California A 35kD TUMOR ASSOCIATED PROTEIN ANTIGEN: USES AND METHODS OF DETECTION
US5723115A (en) * 1991-05-02 1998-03-03 W. Alton Jones Cell Science Center, Inc. Inhibition of adipose tissue development and obesity
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) * 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5283066A (en) * 1992-02-19 1994-02-01 Development Center For Biotechnology Method of stimulating an immune response by using a hapten
CA2098960C (en) * 1992-07-10 2004-11-02 Richard Barner Bio specifically recognizing surfaces on solid supports and method for their preparation
US6306421B1 (en) 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
ES2355184T3 (es) 1993-01-28 2011-03-23 Boston Scientific Limited Inhibidores terapéuticos de células de músculo liso vascular.
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6663881B2 (en) 1993-01-28 2003-12-16 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US7611533B2 (en) 1995-06-07 2009-11-03 Cook Incorporated Coated implantable medical device
GB9606425D0 (en) * 1996-03-27 1996-06-05 Binding Site Ltd Improvements in and relating to the production of antibodies and test kits incorporating antibodies
US7361346B1 (en) * 1996-05-15 2008-04-22 Altarex Corp. Therapeutic compositions that produce an immune response
US8038994B2 (en) * 1996-05-15 2011-10-18 Quest Pharmatech Inc. Combination therapy for treating disease
US7318921B2 (en) * 1996-05-15 2008-01-15 Altarex Medical Corp. Therapeutic compositions that alter the immune response
US20080220012A1 (en) * 1996-05-15 2008-09-11 Ragupathy Madiyalakan Therapeutic Compositions that alter the immune response
US20060159688A1 (en) * 1996-05-15 2006-07-20 Ragupathy Madiyalakan Method for diagnosing efficacy of xenotypic antibody therapy
US6241985B1 (en) * 1996-05-15 2001-06-05 Altarex Corp. Method and composition for reconforming multi-epitopic antigens to initiate an immune response
WO1998043618A2 (en) 1997-03-31 1998-10-08 Neorx Corporation Use of cytoskeletal inhibitors for the prevention of restenosis
EP2386565A3 (en) 1999-01-12 2013-11-20 Cambridge Enterprise Ltd. Compounds and methods to inhibit or augment an inflammatory response
US7009040B2 (en) * 2003-01-21 2006-03-07 Arius Research, Inc. Cancerous disease modifying antibodies
US6613083B2 (en) 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
CA2481796A1 (en) * 2002-04-11 2003-10-23 Altarex Medical Corporation Binding agents and their use in targeting tumor cells
US7393531B2 (en) * 2003-01-21 2008-07-01 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP
US7468254B2 (en) * 2003-01-21 2008-12-23 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP
JP3600231B1 (ja) * 2003-09-30 2004-12-15 森永製菓株式会社 イムノアッセイ
WO2019199918A1 (en) * 2018-04-11 2019-10-17 Cowan Fred M Compositions and methods for prevention and treatment of immune complex disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3063736D1 (en) * 1979-03-27 1983-07-21 Nat Res Dev Improvements in or relating to immunological preparations
IL63220A (en) * 1981-07-01 1985-09-29 Yeda Res & Dev Process for production of polyacrolein microspheres
US4471058A (en) * 1982-07-26 1984-09-11 Board Of Trustees Operating Michigan State University Method for the detection and/or determination of a polyvalent antigen using at least two different monoclonal antibodies
US4693966A (en) * 1983-03-11 1987-09-15 Sloan-Kettering Institute For Cancer Research Human monoclonal antibodies from lymphocytes of patients with malignant melanoma
FR2558165B1 (fr) * 1984-01-17 1986-07-04 Anvar Nouveaux conjugues d'oligo-muramylpeptides et compositions biologiques les contenant pour l'activation des macrophages

Also Published As

Publication number Publication date
EP0251065A2 (en) 1988-01-07
CN87105716A (zh) 1988-06-08
JPS63258496A (ja) 1988-10-25
DK315187D0 (da) 1987-06-19
NO872581D0 (no) 1987-06-19
AU615628B2 (en) 1991-10-10
DK315187A (da) 1987-12-21
US4879225A (en) 1989-11-07
AU7449687A (en) 1987-12-24
EP0251065A3 (en) 1989-08-30

Similar Documents

Publication Publication Date Title
NO872581L (no) Et produksjon av antistoffer ved anvendelse av insolubil iserte immunkomplekser.
ES8206856A1 (es) Mejoras en un metodo y su correspondiente equipo de ensayo para determinar antigenos por medio de una reaccion inmuno- quimica
DK0677533T3 (da) Antistoffer mod epitoper med homologi til selv-antigener, fremgangsmåder til fremstilling og anvendelser deraf
PT86792A (pt) Monoclonal antibodies against melanoma-associated antigens hybrid cell lines producing these antibodies and use therefor
EP0286099A3 (en) Monoclonal antibodies reactive with endotoxin core
JPS6463393A (en) Monoclonal antibody
KR860003021A (ko) B형 간염 표면항원(HBsAg)에 대한 모노클로널 항체의 제조방법
WO1999013907A3 (en) Methods to improve immunogenicity of antigens and specificity of antibodies
CA2113383A1 (en) Immunometric determination of an antigen or hapten
DE68922806D1 (de) Monoklonale antikörper und herstellung eines impfstoffes gegen menschliche krebsantigene durch immunisierung mit menschlichem und tierischem mucin und mit synthetischen gluciden-trägerkonjugaten.
EP0104014A3 (en) Cell surface antigens of human astrocytoma
DE69026875D1 (de) Immunobestimmung von menschlichem osteocalcin, reagenz und satz dafür
DE69633976D1 (de) Monoklonale antikörper und antigene mit bezug zum menschlichen lungenadenokarzinom und immunoassay-verfahren unter verwendung desselben
EP0323802A3 (en) Monoclonal antibodies against, and cell surface antigen of, lung carcinoma
ES2061664T3 (es) Anticuerpos monoclonales que reconocen a alfa-hanp y correspondientes hibridomas, su preparacion y uso.
GB2199833A (en) Preparation of monoclonal antibodies
JPS57208458A (en) Labeled antibody for immunochemical measurement
DE68926813D1 (de) Von gemeinsamen sequenzen von antigenen und antiidiotypischen antikörpern oder von antikörpern mit spezifizität für die zellulären rezeptoren der antigene abgeleitete immunogene und biologisch aktive peptide
FI860937A (fi) Menetelmä ja reagenssi follikkelia stimuloivan hormonin määrittämiseksi sekä tähän tarkoitukseen sopivat monoklonaaliset vasta-aineet
AU7485987A (en) Method for producing monoclonal antibodies to an immunogenic antibody-antigen conjunction
EP0322102A3 (en) Methods of improved antigen capture assays and compounds therefor
WO1988007058A1 (en) Anti-paratopic antibody as an immunogen
NO903820L (no) Fremgangsmaate for paavisning av analytter.
EP0186371A3 (en) Monoclonal antibodies specific to antigens of hepatitis b virus
JPH03279400A (ja) モノクローナル抗体の作製方法